68 related articles for article (PubMed ID: 38292626)
1. A systematic literature review of 74 Chinese blastic plasmacytoid dendritic cell neoplasm patients.
Gong C; Liu Y; Zhang M
Ther Adv Hematol; 2024; 15():20406207241251602. PubMed ID: 38832237
[TBL] [Abstract][Full Text] [Related]
2. A Case Series of Blastic Plasmacytoid Dendritic Cell Neoplasia.
Serio B; Giudice V; D'Addona M; Guariglia R; Gorrese M; Bertolini A; D'Alto F; Cuffa B; Pellegrino D; Langella M; Selleri C
Transl Med UniSa; 2020 Oct; 23():63-66. PubMed ID: 33457326
[TBL] [Abstract][Full Text] [Related]
3. Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm - collected cases from a single center and case reports.
Faustmann P; Schroeder JC; Mix L; Harland L; Riedel A; Vogel W; Lengerke C; Wirths S
Front Oncol; 2024; 14():1384172. PubMed ID: 38665943
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies.
Kharfan-Dabaja MA; Pemmaraju N; Mohty M
Clin Hematol Int; 2019 Mar; 1(1):2-9. PubMed ID: 34595405
[TBL] [Abstract][Full Text] [Related]
5. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C
Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine maintenance therapy for blastic plasmacytoid dendritic cell neoplasm allograft: A case report.
Tao LL; Wen HT; Wang ZY; Cheng J; Zhao L
World J Clin Cases; 2024 Jan; 12(1):136-141. PubMed ID: 38292626
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy Combined with Venetoclax Followed by Allo-Hematopoietic Stem Cell Transplantation for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang LL; Wang QX; Guan J; Zhou Y; Hu B; Feng Y; Zou L; Cheng H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1531-1536. PubMed ID: 37846712
[TBL] [Abstract][Full Text] [Related]
8.
Chen J; Zhang X; Ma L; Gao Y; Fu Z; Liu M
Front Med (Lausanne); 2023; 10():1258310. PubMed ID: 37663666
[TBL] [Abstract][Full Text] [Related]
9. Case Report of Anti-CD123 Chimeric Antigen Receptor T-Cell Therapy Followed by Radiotherapy for a Recurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem Cell Transplantation.
Jiang YL; Li Q; Yuan T; Jiang YY; Deng Q
Onco Targets Ther; 2020; 13():3425-3430. PubMed ID: 32368098
[TBL] [Abstract][Full Text] [Related]
10. Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm.
Huang X; Wang S; Xu Y; Mei C; Han Q; Wu X; Du F; Ren Y; Jin J; Tong H; Qian J
Ann Hematol; 2024 Jun; 103(6):2165-2168. PubMed ID: 38584216
[TBL] [Abstract][Full Text] [Related]
11. Blastic Plasmacytoid Dendritic Cell Neoplasm in Long-Term Complete Remission After Venetoclax Monotherapy.
Sasaki Y; Murai S; Shiozawa E; Yamochi T; Hattori N
Cureus; 2024 Jan; 16(1):e52446. PubMed ID: 38371152
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study.
Lu Y; Sun RJ; Zhang JP; Xu F; Du ZC; Tong GL; Wang Y; Lu DP
Leuk Lymphoma; 2022 Dec; 63(13):3092-3099. PubMed ID: 36067510
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy for AML after allogeneic HCT.
Nayak RK; Chen YB
Front Oncol; 2022; 12():895771. PubMed ID: 36016625
[TBL] [Abstract][Full Text] [Related]
14. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
Khoury JD; Solary E; Abla O; Akkari Y; Alaggio R; Apperley JF; Bejar R; Berti E; Busque L; Chan JKC; Chen W; Chen X; Chng WJ; Choi JK; Colmenero I; Coupland SE; Cross NCP; De Jong D; Elghetany MT; Takahashi E; Emile JF; Ferry J; Fogelstrand L; Fontenay M; Germing U; Gujral S; Haferlach T; Harrison C; Hodge JC; Hu S; Jansen JH; Kanagal-Shamanna R; Kantarjian HM; Kratz CP; Li XQ; Lim MS; Loeb K; Loghavi S; Marcogliese A; Meshinchi S; Michaels P; Naresh KN; Natkunam Y; Nejati R; Ott G; Padron E; Patel KP; Patkar N; Picarsic J; Platzbecker U; Roberts I; Schuh A; Sewell W; Siebert R; Tembhare P; Tyner J; Verstovsek S; Wang W; Wood B; Xiao W; Yeung C; Hochhaus A
Leukemia; 2022 Jul; 36(7):1703-1719. PubMed ID: 35732831
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD123 in BPDCN: an emerging field.
DiPippo AJ; Wilson NR; Pemmaraju N
Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
